Plus   Neg

AstraZeneca Reports Positive Lung Cancer Drug Data From Phase III FLAURA Trial

Drug maker AstraZeneca (AZN) announced the full results of Phase III FLAURA trial, which support TAGRISSO's clear potential as a new standard of care (SoC) in the 1st-line treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

U.S. shares of AstraZeneca rose 1.98% in the extended session Friday after the drug maker released promising results from the study.

The company specified that phase III FLAURA trial results show TAGRISSO reduced the risk of progression or death by more than half, with consistent results across all subgroups, including those with and without brain metastases

Superior median progression-free survival (PFS) of 18.9 months compared with 10.2 months for the current standard of care, the company said in a late-stage clinical trial.

For comments and feedback contact: editorial@rttnews.com

Health News


0 Articles
Follow RTT